OSE — Ose Immunotherapeutics SA Income Statement
0.000.00%
Last trade - 00:00
- €119.99m
- €147.12m
- €2.23m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 26 | 10.4 | 26.3 | 18.3 | 2.23 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 27.4 | 29.4 | 42.9 | 36.8 | 25.2 |
Operating Profit | -1.47 | -19 | -16.6 | -18.5 | -23 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.46 | -19.2 | -17.2 | -18 | -23.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.65 | -16.6 | -16.8 | -17.8 | -23 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.65 | -16.6 | -16.8 | -17.8 | -23 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.65 | -16.6 | -16.9 | -17.8 | -23 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.312 | -1.06 | -0.916 | -0.952 | -1.18 |
Dividends per Share |